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S u m m a r y
Renal Cell Carcinoma (RCC) derives from various parts of the nephron. The incidence of RCC increases by an average of 
2% per year and accounts for 2% to 3% of all adult malignant neoplasms. The implementation of ultrasonography and com-
puted tomography increased the number of fortuitous diagnoses of RCCs which are called Incidental Renal Tumours (IRT). 
Such tumours are usually smaller than symptomatic ones. Surgical treatment is the best option for the primary tumour. The 
type of surgical treatment depends of the stage of the tumour. However, the technique of surgical treatment has changed 
recently. The trend is to decrease the extent and invasiveness of surgery without affecting the oncological safety in patients 
with localized RCC. On the other hand there is indication for aggressive treatment in patients with locally advanced disease. 
Tumour nephrectomy is also recommended for metastatic RCC patients with good performance status when combined with 
IFN – alpha. Complete removal of metastatic lesions or isolated local recurrences after partial nephrectomy or radical ne-
phrectomy contribute to an improvement of clinical prognosis. 
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S t r e s z c z e n i e
Rak nerkowokomórkowy (RCC – renal cell carcinoma) powstaje zwykle z komórek nabłonka proksymalnych kanalików 
krętych nefronu. RCCs stanowią nie mniej niż 3% wszystkich nowotworów złośliwych, a zapadalność na ten nowotwór zwięk-
sza się w Europie o 2% rocznie. Od czasu rozpowszechnienia ultrasonografii i tomografii komputerowej zwiększyła się liczba 
chorych, u których guzy nerki rozpoznaje się przypadkowo u osób, u których wspomniane badania wykonywane są z innych 
powodów niż „urologiczne”. Guzy rozpoznane przypadkowo (IRT – incidental renal tumors), zwane także „guzami radiolo-
gicznymi”, są zwykle mniejsze od guzów „objawowych”. Jedyną metodą pierwotnego leczenia RCCs jest leczenie chirur-
giczne, przy czym zakres i rodzaj operacji zależą głównie od stopnia zaawansowania raka. Zasady leczenia operacyjnego 
chorych na RCC uległy w ostatnich latach istotnym zmianom. Z jednej strony polegają one na ograniczeniu inwazyjności i 
zakresu operacji u chorych, u których rozpoznaje się guz ograniczony do nerki, aczkolwiek bez zmniejszenia jej skuteczności 
onkologicznej, z drugiej natomiast na możliwie jak najbardziej agresywnym leczeniu operacyjnym tych chorych, u których 
nowotwór jest zaawansowany miejscowo. Dynamiczne leczenie operacyjne ma także zastosowanie u chorych, u których 
stwierdza się współistnienie przerzutów odległych, jeśli stan chorych pozwala na poddanie ich operacji, a także u chorych, u 
których po częściowym wycięciu nerki wraz z guzem lub po nefrektomii radykalnej dochodzi do wznowy miejscowej nowo-
tworu lub do przerzutów odległych, które można wyciąć. 
Słowa kluczowe: rak nerkowokomórkowy, nefrektomia radykalna, częściowa resekcja nerki
In 2009, the incidence of malignant tumours aris-
ing from the renal parenchyma in Poland is estimated 
to have been 14.8/100 000 in men and 9.5/100 000 in 
women, while the associated death rates were 8.4/100 
000 and 5.0/100 000, respectively (1). Among renal tu-
mours, the dominating renal cell carcinoma (RCC) aris-
es from the proximal canaliculi of the nephron. RCCs 
comprise at least 3% of all malignant neoplasms (2), 
while their incidence in Europe grows annually by 2% 
(3). RCC occurs 1.5-2 times more frequently in men 
compared to women (4), and the incidence rises in the 
sixth and seventh decades of life (5). The main risk fac-
tors of RCC are tobacco smoking, obesity and arterial 
hypertension (6, 7). In the majority of patients, RCC is a 
sporadic tumour, with only 2-3% occurring in a familial 
background (7). 
“Renal cell carcinoma” is a broad term. It encom-
passes several histologically dissimilar tumours. The 
one with the highest incidence is clear cell carcinoma 
(CCC), which makes up 70-80% of all RCCs. The re-
maining types are papillary cancer (10-15%), chro-
mophobic cancer (3-5%) and an exceptionally malig-
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nant cancer arising from the collecting duct epithelium 
(collecting duct carcinoma), also known as Bellini’s 
tumour (< 1 %) (8). 
The signs and symptoms associated with solid renal 
tumours are not characteristic. The main ones include 
pain, haematuria, and a palpable mass in the kidney 
region, collectively known as Israel’s triad. Tumours 
found when diagnostic workup was induced by symp-
toms are usually advanced. Ever since ultrasound and 
computed tomography imaging became widely avail-
able, there is a growing number of cases identified ac-
cidentally by studies performed for “non-urological” 
indications. Incidental renal tumours (IRT), also called 
“imaging tumours”, are usually smaller than “symp-
tomatic” tumours. The proportion of fortuitously diag-
nosed tumours in the total number of diagnosed renal 
tumours is currently approx. 60% (9,10). 
The only method of primary treatment of RCC is sur-
gery, while the type and scope of the operation depend 
chiefly on the disease stage. The grading of the can-
cer based on a four-grade Fuhrman scale (11) can be 
determined after tumour excision, since percutaneous 
lesion biopsy is not deemed to be a part of standard 
preoperative management. The latter is only applied 
when the tumour is to be removed by a minimally inva-
sive method executed through thermal ablation. 
Less advanced stages and smaller sizes of RCCs at 
the time of diagnosis as well as a better understanding 
of the biology of these tumours has encouraged the 
search for surgical methods that would be less inva-
sive and more limited in scope compared to the classic 
radical nephrectomy (RN), which has been the main-
stay of treatment. Currently, in cases with a favourable 
anatomical location of the tumour, which measures no 
more than 7 cm in its largest diameter, nephron-spar-
ing surgery is advocated (NSS). 
PARTIAL NEPHRECTOMy
The pioneer of partial nephrectomy (PN), also known 
as kidney resection, is Vincent Czerny, who performed 
a renal parenchyma-sparing operation in 1887. Howev-
er, this method was not broadly adopted due to numer-
ous complications. Currently, PN is recommended for 
tumours measuring up to 4 cm in diameter (cT1a) and 
is a method of choice for tumours measuring between 
4 and 7 cm, which are limited to the kidney (cT1b), 
provided that it is technically feasible (12-24). The oc-
currence of major complications, which were reported 
earlier, has been greatly reduced by the advent of new 
techniques, devices and materials, however, the risk 
of their emergence should not be ignored. They can 
include secondary bleeding from the resected kidney, 
and urinary or arterio-venous fistulas, which may lead 
to serious haematuria. The fundamental advantage of 
PN is the preservation of the unaffected part of the kid-
ney. This markedly reduces the risk of chronic renal 
failure, which may emerge with varied delay following 
total nephrectomy, especially in patients with diabetes, 
atherosclerosis or arterial hypertension (25). Accord-
ing to some authors, the quality of life of patients sub-
jected to PN is superior to that of patients treated by 
radical nephrectomy (26, 27). Moreover, the execution 
of surgery with a short period of renal ischaemia usu-
ally does not impair renal function (28).
Until recently, the indications for PN were limited to 
the so-called absolute kind and included tumours de-
veloping in an anatomically or functionally single kid-
ney (i.e. absence of the contralateral kidney or failure 
or complete lack of function of the contralateral kid-
ney), as well as a bilateral RCC. Currently, these have 
been broadened to include relative indications, which 
regard patients with a risk of future failure of the contral-
ateral kidney; or with a genetic defect, which increases 
the risk of renal tumours developing in the future, as 
in syndromes like von Hippel-Lindau, hereditary pap-
illary RCC, familial leiomyomatosis, Birt-Hogg-Dubé 
(29, 30); as well as elective indications, such as the 
technical feasibility and safety of PN in patients, whose 
contralateral kidney is intact (12). 
Partial nephrectomy can involve the resection of the 
inferior, superior, or even central fragment of the kid-
ney, which contains the tumour, together with a mar-
gin of macroscopically unaltered renal parenchyma 
(a margin of 1 mm is sufficient). It is performed retro-
peritoneally via lumbotomy (open surgery) or, with in-
creasing frequency, by laparoscopy or retroperitone-
oscopy (endoscopic surgery without opening of the 
peritoneal cavity). Surgery is performed in conditions 
of ischaemia achieved after clamping the major ves-
sels of the renal pedicle, or preferably, if possible, the 
selective clamping of vessels supplying the resected 
fragment of the kidney. The duration of ischaemia is 
critically important for the later function of the resect-
ed kidney. In the case of so-called “warm ischaemia”, 
its duration should not exceed 20 minutes (31). On 
the other hand, if “cold ischaemia” is applied by pack-
ing the kidney with sterile crushed ice, its duration can 
be safely extended up to 60 minutes (32). PN reduces 
the risk of renal failure. McKiernan et al. performed 
a 10-year prospective study, which enrolled 290 pa-
tients with RCC measuring up to 4 cm, in whom the 
contralateral kidney was normal. The study compared 
173 patients treated by radical nephrectomy (RN) with 
a group of 117 patients treated by PN. The former 
group had a higher risk of developing chronic renal 
failure, compared to the latter group (33). Dash et al. 
performed a prospective study, which followed 196 
subjects with RCC measuring 4-7 cm, in whom either 
RN or PN was performed. They found that 3 months 
post-op, creatinine levels were significantly lower in 
patients treated with PN (20). Nevertheless, the most 
important goal regarding PN is to achieve long-term 
oncological outcomes that match classic radical neph-
rectomy. Lee et al. compared PN and RN outcomes in 
patients with RCC tumours measuring < 4 cm finding 
that 5-year survival without local recurrence is compa-
rable for both types of treatment (34). Many other pa-
pers have reported similar outcomes of PN and RN in 
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patients operated for tumours measuring < 7 cm (13, 
17, 18, 20, 22, 24).
The alternative to and open PN is endoscopic sur-
gery (LPN – laparoscopic partial nephrectomy). Re-
cently, LPN has been gaining increasing popularity 
and specialised centres use it to treat the majority 
of patients operated for small RCCs. The choice of 
endoscopic approach to the kidney depends on the 
tumour’s location. In the majority of cases, surgery is 
performed transperitoneally. If the tumour is located 
on the posterior or postero-medial aspect of the kid-
ney, it can be accessed by retroperitoneal approach 
(retroperitoneoscopy) although this involves techni-
cal difficulties due to a limited surgical field (35). With 
LPN, the ischaemic kidney is not cooled. Therefore, 
the planning of LPN must consider whether the funda-
mental part of the procedure can be performed during 
an appropriately short ischaemic period. Oncological 
outcomes of LPN in an excellent nephro-oncology cen-
tre are similar to those achieved with open PN (36) but 
it should be borne in mind that LPN requires technical 
skill and a significant experience in laparoscopy. Au-
thors from the above-mentioned centre have recently 
presented an interesting report on the outcomes of 
LPN performed in 1,000 patients with RCC operated 
over 9 years. The patients were split into 3 groups by 
time the period in which they were treated. Compar-
ing the group treated in the earliest period with the 
two other groups, the authors found that the recently 
excised tumours were more challenging for the sur-
geons (they were larger, measuring > 4 cm and were 
located closer to the vascular pedicle of the kidney). 
This points to a significant impact of experience on the 
safety and effectiveness of the surgery. Despite being 
a more technically difficult group, these patients had 
a shorter time of warm ischaemia during surgery and 
less complications. The proportion of positive surgi-
cal margins in that group was only 0.6%. The 5-year 
recurrence-free survival for the three groups was 
90%, 99% and 97%, respectively (37). The compari-
son of open PN with LPN in a group of 1,800 patients 
showed that the laparoscopic surgery took less time 
(200 min vs. 258 min – p < 0.0001), it involved less 
blood loss (300 ml vs. 376 ml – p. < 0,0001), however, 
the duration of warm ischaemia was longer (31 min vs. 
20 min – p. < 0,0001), and the proportions of patients 
developing “urological” complications, requiring fur-
ther surgery as a result or suffering a post-op bleed 
were higher. The percentages were 9.2% vs. 5.0% 
(p < 0.006), 7.0% vs. 3.5% (p < 0.0001) and 4.2% vs. 
1.6% (p < 0.0002), respectively (38). Nevertheless, 
the risk-benefit ratio suggests that LPN applied to 
treat well-selected patients is more attractive for them 
compared to open PN. Hence, the list of indications 
for LPN is gradually expanded. Initially the procedure 
was applied for small tumours (cT1a), while currently, 
it is used for tumours measuring 4-7 cm (cT1b), and 
even tumours that are larger (cT2) (39). At the same 
time, it is underscored that if difficulties emerge during 
LPN, the procedure should be converted to open ac-
cess and completed with the kidney preserved rather 
than continued as LPN with kidney excised (40). The 
latest technique used for endoscopic PN is robotic 
partial nephrectomy (RPN). The outcomes in patients 
treated that way seem promising (12). 
Many papers confirm that the oncological outcomes 
in patients treated by PN vs. RN are comparable. 
Moreover, they point to the lower risk renal failure in 
patients with preserved renal parenchyma. However, 
none of these studies was randomised. A recent report 
discusses the first randomised study to compare the 
oncological outcome in 541 subjects who underwent 
PN (n=268) or RN (n=273), for tumours measuring 
no more than 5 cm in diameter. Surprisingly, a slightly 
higher proportion of 10-year survival was found in the 
RN group, compared to PN (79.4% vs. 75.2%, statisti-
cally insignificant). Nevertheless, both methods offered 
very good oncologic outcomes (41).
RADICAL NEPHRECTOMy
The first nephtectomy for a renal tumour was per-
formed by Gustav Simon in 1869. Until the mid-1900s, 
the surgery was executed via a retroperitoneal ap-
proach (lumbotomy), because at the time, laparo-
tomy carried a high risk of peritonitis. As of 1950, the 
transperitoneal approach gained popularity. In 1969, 
Robson presented his concept of the scope of radi-
cal nephrectomy (RN), which was accepted for many 
years. It involved the laparotomy approach, removal of 
the kidney with its fatty capsule, the suprarenal gland, 
regional lymph-nodes and both laminae of Gerota’s 
fascia (42). As oncologic follow-up data of this broad 
radical nephrectomy were collected, and as the num-
bers of patients with early-stage disease grew, the 
range of RN was revisited. Gradually, the indications for 
lymphadenectomy and adrenalectomy, as part of RN, 
became limited. Currently, adrenalectomy is performed 
only where there is direct renal tumour spread to the 
adrenal gland or if the gland is believed to harbour 
metastases. Regional lymphadenectomy is performed 
whenever the intraoperative evaluation and/or preop-
erative diagnostics are consistent with lymphadenopa-
thy. This followed the finding of evidence that a routine 
performance of an extensive lymphadenectomy in the 
absence of macroscopic lesions in the lymph nodes 
does not improve cancer-specific mortality. The exci-
sion of macroscopically unchanged regional lymph 
nodes is meaningful for the pathological staging of 
RCC. It must be underscored that the presence of me-
tastases in lymph nodes is one of the most important 
predictors of poor risk in RCC patients without distant 
metastases. 
Earlier, in the case of very large tumours, especially 
ones that created a venous thrombus of malignant tis-
sue, the renal artery would be embolised prior to sur-
gery in order to limit bleeding during the operation. For 
over a decade, thanks to the development of surgical 
technique, this solution is no longer advocated. How-
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ever, embolization remains indicated, when reccurent 
haematuria occurs in connection with a renal tumour, 
which cannot be treated with RN (12). 
Open RN is indicated for a renal tumour that in-
filtrates the perirenal fatty tissue, the adrenal gland, 
the renal vein and/or the vena cava as well as neigh-
bouring structures (43). If RN is performed for a large 
tumour, its success depends on an unrestricted ac-
cess to the kidney and its vascular pedicle. This is 
provided by laparotomy, which allows for expedited 
ligation and division of the renal artery. The choice 
of the surgical incision (Chevron, hemi-Chevron or 
even an abdomino-phreno-thoracic incision) depends 
on the size and location of the tumour as well as the 
urologist’s preferences. In some patients, access via 
lumbotomy is sufficient, although the majority could 
be successfully treated with laparoscopic RN (LRN). 
The risk of complications related to RN is high, how-
ever, it depends on the size and stage of the tumour 
and the patient’s preoperative condition. Van Poppel 
et al., in a prospective randomised clinical trial (com-
parison of open RN with LRN in patients with RCC 
measuring < 5 cm), found that the loss of < 500 ml or 
> 1000 ml of blood during surgery occurred in 96 % 
and 1.2 %, respectively, while damage to the pleura 
and spleen during open RN was noted in 9.3 % and 
0.4 %, respectively (44). 
The first LRN was performed by Clayman in 1990, in 
Washington. Currently, this procedure is the standard 
of care in patients with RCC clinically staged as locally 
advanced, i.e. cT2 (tumours > 7 cm in diameter, lim-
ited to the kidney) as well as smaller tumours, if PN is 
not feasible (12). Nonetheless, in specialised centres, 
LRN is performed for large, locally advanced tumours 
(cT > 2), and even tumours that have spread into the 
renal vein, and in debulking treatment (45). The proce-
dure can be performed through a trans- or retroperito-
neal approach. Two prospective studies have shown 
that the time needed to perform retroperitoneal LRN is 
shorter in comparison to transperitoneal LRN, although 
the outcomes and complications of the two procedure 
types turned out to be identical (46, 47). 
The comparison of open RN with LRN performed for 
tumours confined to the kidney has found no significant 
differences with regard to oncological outcomes (48). 
Burgess et al. performed the first randomised study 
comparing open RN with LRN. The mean maximum 
diameter of the tumours was 8 cm. Both groups con-
sisted of 45 patients. No significant differences were 
found regarding blood loss, mortality, surgery duration, 
or duration of post-op hospital stay. However, patients 
operated by laparoscopy suffered less post-op pain 
and their rehabilitation period was shorter (49). Anoth-
er prospective study comparing patients operated for 
stage cT2 RCC by open RN or LRN, found that 5-year 
survival in either group was identical, whereas the lap-
aroscopy group suffered less blood loss, required less 
analgesic treatment, had a shorter hospitalisation and 
rehabilitation time (50). 
There is a modification of LRN, which is worth men-
tioning. This involves surgery that is assisted by the 
surgeon’s hand, which is introduced through a small, 
air-tight incision in the abdominal integument (H-ALRN 
– hand-assisted LRN). Matin et al. performed a retro-
spective analysis of 271 patients operated either by H-
ALRN or LRN. They found that with H-ALRN the dura-
tion of surgery was shorter but post-op pain intensity 
was higher and post-op hospital stay was longer (51). 
Ultimately, it seems that the use of H-ALRN should not 
be advocated.
On the other hand, great expectations are associated 
with robotic radical nephrectomy (RRN). Hamal et al., 
in a prospective comparison of RRN and LRN, found 
that the results, including oncological outcomes, were 
similar, although the RRN procedure involved higher 
costs and took longer to complete. The study found no 
advantages of RRN compared to LRN (52).
LOCALLy ADVANCED RENAL CANCER
Despite of the increased proportion of small, as-
ymptomatic tumours in the overall number of cases, 
locally advanced and/or metastatic RCCs continue to 
be diagnosed. In some patients, the renal vein or the 
vena cava contain ingrown tumour masses, and/or the 
tumour has spread to neighbouring organs including 
lymph nodes. RCCs are also classified as advanced in 
patients who sustain local tumour recurrence following 
prior surgical treatment (53).
In about 10% of RCC patients, the tumour has 
spread into the lumen of the renal or caval vein, while in 
1 % the malignant growth reaches the right atrium (54). 
Intraluminal tumour growth is best identified and as-
sessed for scope with MRI. Such imaging allows for the 
planning of surgical tactics (55). The only treatment op-
tion for patients with a venous tumour thrombus is the 
surgical removal of the tumour with the whole venous 
ingrowth (56). In itself, the presence of the ingrowth 
is not an independent prognostic factor and post-op 
survival chiefly depends on the specific characteristics 
of the primary tumour, less on the size of the ingrowth 
(57). 
If lymph nodes are involved, lymphadenectomy may 
be therapeutically beneficial. In such cases, lymph 
node excision improves patient survival and helps 
identify those who qualify for systemic adjuvant treat-
ment. If distant metastases are present, lymphadenec-
tomy comprises an additional cytoreduction measure 
(40). Pantuck et al. found that in patients with RCC 
metastases to the lymph nodes and distant organs, 
lymphadenectomy and systemic immunotherapy with 
interleukin 2 prolongs survival by a mean of 5 months 
compared to patients treated by RN alone (58). 
Renal tumours, which infiltrate neighbouring struc-
tures without causing distant metastases, are rare 
and comprise about 1-1.5% of all locally advanced 
RCC cases (59,60). Capitanio et al. presented a se-
ries of 310 patients with T4N0-2 stage RCC, of whom 
246 were treated surgically and 64 were treated con-
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servatively. The survival of the surgical patients was 
48 months, while the symptomatically treated survived 
only 6 months (61). Overall, patients with RCC tu-
mours, which infiltrate neighbouring structures should 
undergo a broad nephrectomy with the removal of all 
involved tissues in one block (40). 
SUMMARy
The principles of surgical treatment in patients with 
RCC have recently undergone significant changes. 
On the one hand, the invasiveness and the scope of 
the surgery have been limited in patients diagnosed 
as having an organ-confined tumour with no loss of 
oncological effectiveness. On the other hand, highly 
aggressive surgery is advocated for patients with lo-
cally advanced tumours. A dynamic course of surgical 
management is applicable in patients who are found to 
have distant metastases, whenever the patient’s condi-
tion allows for surgery. A similar approach is suggest-
ed for patients who, having undergone partial or radi-
cal nephrectomy, develop a local recurrence or distant 
metastases amenable to resection. 
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